<br>        Inclusion Criteria:<br><br>          -  Men or women 18 to 75 years of age at the time of informed consent signature<br><br>          -  Confirmed diagnosis of RA according to 2010 American College of Rheumatology (ACR)/The<br>             European League Against Rheumatism (EULAR) RA classification criteria of at least 6<br>             months duration<br><br>          -  Positive RF and/or anti-CCP (anti-cyclic citrullinated peptide)<br><br>          -  Persistently active disease defined as greater than equal to (>=) 6 swollen joints (of<br>             66 counted) and >= 6 tender joints (of 68 counted)<br><br>          -  High-sensitivity C-reactive protein (hsCRP) >= 3.6 milligram per liter (mg/L)<br><br>          -  Treatment for >= 12 weeks with 10 to 25 mg/week MTX at a stable dose for at least 4<br>             weeks prior to dosing with the investigational medicinal product (IMP) and maintained<br>             throughout the trial<br><br>          -  Women of childbearing potential must use acceptable methods of contraception for 4<br>             weeks prior to randomization, throughout the trial, and for 90 days after the last<br>             dose of IMP. For the purposes of this trial<br><br>          -  Females who are postmenopausal (age-related amenorrhea >= 12 consecutive months and<br>             increased follicle-stimulating hormone [FSH] greater than (>) 40 milli international<br>             units per milliliter [mIU/mL]), or who have undergone hysterectomy or bilateral<br>             oophorectomy are exempt from pregnancy testing. If necessary to confirm postmenopausal<br>             status, an FSH will be drawn at Screening<br><br>          -  Acceptable contraception is defined as use of either 2 barrier methods (eg, female<br>             diaphragm and male condom), or 1 barrier method in conjunction with one of the<br>             following: spermicide, an intrauterine device, or hormonal contraceptives (implant or<br>             oral)<br><br>          -  Women of childbearing potential must have a negative serum pregnancy test at the<br>             Screening Visit and a negative urine pregnancy test at Day 1/randomization before<br>             dosing.<br><br>        Exclusion Criteria:<br><br>          -  Use of oral corticosteroids > 10 mg daily prednisone equivalent, use of injectable<br>             corticosteroids, or change in dose of corticosteroids within 2 weeks prior to<br>             Screening or during Screening<br><br>          -  Initiation or change in dose for nonsteroidal anti-inflammatory drugs (NSAIDs) within<br>             2 weeks prior to Screening<br><br>          -  Treatment with tofacitinib, other Bruton's Tyrosine Kinase (BTK) inhibitors, or a<br>             biologic disease-modifying antirheumatic drug (DMARD; eg, anti-tumor necrosis factor<br>             alpha [anti-TNF-a], tocilizumab [anti-interleukin-6 receptor], abatacept [CTLA4-Fc]),<br>             or other immunosuppressive drugs(sulfasalazine would be acceptable at a stable dose)<br>             other than methotrexate within 3 months prior to Screening or during Screening<br><br>          -  Treatment with anti-CD20 therapy (eg, rituximab) within 12 months prior to Screening<br>             or during Screening<br><br>          -  Immunologic disorder other than Rheumatoid Arthritis (RA), with the exception of<br>             secondary Sjogren's syndrome associated with RA, and well-controlled diabetes or<br>             thyroid disorder, or any other condition requiring oral, intravenous, intramuscular,<br>             or intra-articular corticosteroid therapy<br><br>          -  Vaccination with live or live-attenuated virus vaccine within 1 month prior to<br>             Screening<br><br>          -  Active, clinically significant, viral, bacterial, or fungal infection, or any major<br>             episode of infection requiring hospitalization or treatment with parenteral<br>             anti-infectives within 4 weeks of Screening or during Screening, or completion of oral<br>             anti-infectives within 2 weeks before or during Screening, or a history of recurrent<br>             infections (ie, 3 or more of the same type of infection in a 12-month rolling period).<br>             Vaginal candidiasis, onychomycosis, and genital or oral herpes simplex virus<br>             considered by the Investigator to be sufficiently controlled would not be exclusionary<br><br>          -  History of or positive testing for human immunodeficiency virus (HIV), hepatitis C<br>             antibody and/or polymerase chain reaction, hepatitis B surface antigen (HBsAg) (+)<br>             and/or hepatitis B core total, and/or IgM antibody (+) at Screening<br><br>          -  History of or current diagnosis of active tuberculosis (TB); undergoing treatment for<br>             latent TB infection (LTBI); untreated LTBI (as determined by documented results within<br>             3 months of the Screening Visit of a positive TB skin test with purified protein<br>             derivative with induration >= 5 millimeter (mm), a positive QuantiFERON-TB test or<br>             positive or borderline T-SPOT [Elispot] test); or positive QuantiFERON-TB test at<br>             Screening. Participants with documented completed appropriate LTBI treatment would not<br>             be excluded and are not required to be tested<br><br>          -  Participants with current household contacts with active TB will also be excluded<br><br>          -  Indeterminate QuantiFERON-TB or T-SPOT tests may be repeated once, and will be<br>             considered positive if retest results are positive or indeterminate<br><br>          -  History of cancer, except adequately treated basal cell or squamous cell carcinomas of<br>             the skin (no more than 3 lesions requiring treatment in lifetime) or carcinoma in<br>             situ/cervical intraepithelial neoplasia of the uterine cervix, unless considered cured<br>             > 5 years<br><br>          -  Clinically significant abnormality on electrocardiogram (ECG), or an active infective<br>             process or any other clinically significant abnormality on Screening chest X-ray (CXR)<br>             taken within 4 weeks of the first dose, per Investigator opinion. If a CXR has been<br>             taken within the previous 3 months and results are available and normal, the CXR does<br>             not need to be carried out<br><br>          -  B cell (CD19) count less than (<) 50% of the lower limit of normal at Screening<br><br>          -  Significant cytopenia including absolute neutrophil count < 1,500/ mm^3, platelet<br>             count < 100,000/mm^3, or absolute lymphocyte count < 1,000/mm^3<br>